Related Experiment Video

Updated: Mar 21, 2026

Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier
09:00

Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier

Published on: April 5, 2017

21.0K

Fingolimod-associated PML in a patient with prior immunosuppression

Tirisham V Gyang1, Johanna Hamel2, Andrew D Goodman2

  • 1From the University of Rochester Medical Center, Rochester, NY. Tirisham_Gyang@urmc.rochester.edu.

Neurology
|May 11, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
10:50

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Published on: March 26, 2019

8.4K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K

Related Experiment Videos

Last Updated: Mar 21, 2026

Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier
09:00

Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier

Published on: April 5, 2017

21.0K
Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
10:50

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Published on: March 26, 2019

8.4K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K

Related Concept Videos

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

2.7K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

655
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
655

Articles linked to this work by shared authors, journal, and citation graph.

Longitudinal Psychometric Properties of the Myotonic Dystrophy Health Index in a Large Multicenter Cohort of People Living With Myotonic Dystrophy Type 1.

Muscle & nerve·2026

Reversible cerebral vasoconstriction syndrome following ciltacabtagene autoleucel therapy for relapsed multiple myeloma: a case report.

Frontiers in immunology·2026

Prospective Study of Video Hand Opening Time as a Quantitative Measurement of Myotonia in Patients With Myotonic Dystrophy Type 1.

Neurology·2026

Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history study.

PloS one·2025

Study of Testosterone and Recombinant Human Growth Hormone in Facioscapulohumeral Muscular Dystrophy.

Neurology. Genetics·2025

DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial.

Multiple sclerosis (Houndmills, Basingstoke, England)·2025

De-Escalating and Discontinuing Immunotherapies in Patients With NMOSD and MOGAD.

Neurology·2026

EOAD-Signature Atrophy Predicts Dementia in Early-Onset MCI due to Alzheimer Disease: An MRI-Based Prognostic Biomarker.

Neurology·2026

Refining Treatment Monitoring in Patients With Relapsing Multiple Sclerosis Based on Changes on Neurofilament Light Chain Z-Scores.

Neurology·2026

Effect of a ≥50% Reduction in Low-Density Lipoprotein Cholesterol From Baseline in Patients With Ischemic Stroke.

Neurology·2026

The Prognostic Value of Paramagnetic Rim Lesions in People With Multiple Sclerosis.

Neurology·2026

Effect of Baseline ASPECTS on Tenecteplase Efficacy Before Thrombectomy in Acute Large-Vessel Occlusion Stroke: A Post Hoc Analysis of the BRIDGE-TNK Randomized Trial.

Neurology·2026

Acute-onset autoimmune type 1 diabetes presenting with diabetic ketoacidosis in an obese adult.

Proceedings (Baylor University. Medical Center)·2026

Anifrolumab as a therapeutic option in mixed connective tissue disease with autoimmune cytopenia: a case report and narrative review of the literature.

Reumatismo·2026

Adult-onset activated PI3Kδ syndrome presenting with HLH-like hyperinflammation, autoimmunity, and thrombosis: an underrecognized inborn error of immunity.

Haematologica·2026

Elevated Lipoprotein(a) Is Highly Prevalent in Autoimmune or Inflammatory Disease: A Multisite Study.

JACC. Advances·2026

Plasma proteome reflects tissue damage and clinical manifestations in patients with inflammatory myopathies.

Arthritis & rheumatology (Hoboken, N.J.)·2026

Efficacy of the Bispecific Anti-BAFF/IL-21 Antibody CZ105 Bis2 in Models of Systemic Lupus Erythematosus.

Arthritis & rheumatology (Hoboken, N.J.)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us